Bharat Biotech states that covacin is safe for children aged 2 to 18

0
15

 

Covacin, a corona vaccine for children developed by Bharat Biotech International Limited (BBIL), has been found to be safe and disease-resistant, according to the company. The research was accepted and published in the journal ‘Lancet Infectious Diseases,’ according to a news statement released by the vaccine maker.

Bharat Biotech conducted a Phase 2/3 multicenter trial to determine the safety of the Covaccine vaccine when given to healthy children and adolescents aged 2 to 18. Also, how will their body react as a result of this, and what effect will it have on their immune system?

It stated that the vaccine was proven to be safe in trials conducted on children between June 2021 and September 2021, that it had no severe health effects, and that it enhanced immunity. In October 2021, this information was submitted to the Central Drugs Standard Control Organization (CDSCO). It was licenced for emergency usage in children aged six to eighteen.